Pangaea Oncology, S.A. (BME:PANG)

Market Cap	54.23M -7.1%
Revenue (ttm)	16.73M +68.1%
Net Income	-3.60M
EPS	-0.10
Shares Out	35.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	835
Open	1.510
Previous Close	1.560
Day's Range	1.510 - 1.510
52-Week Range	1.510 - 1.750
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About Pangaea Oncology

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx p...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 165
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PANG

Financial Performance

In 2025, Pangaea Oncology's revenue was 16.73 million, a decrease of -0.32% compared to the previous year's 16.79 million. Losses were -3.60 million, 208.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error